DelveInsight Business Research LLP

DelveInsight’s “Familial Adenomatous Polyposis Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Familial Adenomatous Polyposis, historical and forecasted epidemiology as well as the Familial Adenomatous Polyposis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 Familial Adenomatous Polyposis Overview

Familial adenomatous polyposis is an autosomal dominant inherited condition in which numerous adenomatous polyps form mainly in the epithelium of the large intestine. While these polyps start out benign, malignant transformation into colon cancer occurs when they are left untreated. Three variants are known to exist, Familial Adenomatous Polyposis and attenuated Familial Adenomatous Polyposis (originally called hereditary flat adenoma syndrome) are caused by APC gene defects on chromosome 5 while autosomal recessive FAP (or MUTYH-associated polyposis) is caused by defects in the MUTYH gene on chromosome 1. O

 Familial Adenomatous Polyposis Epidemiological Insights 

• The incidence of the mutation is between 1 in 10,000 and 1 in 15,000 births. By age 35 years, 95% of individuals with FAP (>100 adenomas) have polyps. Without colectomy, colon cancer is virtually inevitable. The mean age of colon cancer in untreated individuals is 39 years (range 34–43 years).

• Attenuated FAP arises when APC is defective but still somewhat functional. As a result, it retains part of its ability to suppress polyps. Therefore, attenuated FAP manifests as colorectal cancer unusually late (age 40–70, average=55), and typically with few, or at least far fewer polyps (typically 30), than the more usual version of FAP, at an age when FAP is no longer considered much of a likelihood or risk according to usual FAP epidemiology.

Learn how the market will evolve by 2032 @ Familial Adenomatous Polyposis  Market Trends and Developments

 The Report Covers the Familial Adenomatous Polyposis Epidemiology Segmented by – 

• Familial Adenomatous Polyposis prevalent cases 

• Familial Adenomatous Polyposis incident cases

• Familial Adenomatous Polyposis Treatment cases 

• Familial Adenomatous Polyposis diagnosed cases 

Familial Adenomatous Polyposis Market Outlook 

The Familial Adenomatous Polyposis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Familial Adenomatous Polyposis market trends by analyzing the impact of current Familial Adenomatous Polyposis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Familial Adenomatous Polyposis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Familial Adenomatous Polyposis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Familial Adenomatous Polyposis market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Familial Adenomatous Polyposis Market Includes

• Emtora Biosciences

• Cancer Prevention Pharmaceuticals

• SLA Pharma

And many others 

Familial Adenomatous Polyposis Therapies Covered and Analyzed in the Report:

• REC-4881

• Eicosapentaenoic Acid 

• Eflornithine

And many others 

Read more about the Key Companies and Emerging Therapies in the Familial Adenomatous Polyposis Market 

Table of Contents

1. Key Insights 

2. Familial Adenomatous Polyposis Introduction 

3. Executive Summary of Familial Adenomatous Polyposis 

4. Disease Background and Overview

5. Epidemiology and patient population

6. Familial Adenomatous Polyposis  Emerging Therapies

7. Familial Adenomatous Polyposis  Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10.  Market Barriers 

11.  Appendix

12. Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn more about the detailed offering of the report @ Familial AdenomatousPolyposis  Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services